

# Yoo-Young Lee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/432177/publications.pdf>

Version: 2024-02-01

103  
papers

2,031  
citations

279798

23  
h-index

289244

40  
g-index

106  
all docs

106  
docs citations

106  
times ranked

2896  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Waiting Time from Pathological Diagnosis to Definitive Concurrent Chemoradiation for Cervical Cancer on Overall Survival. <i>Cancer Research and Treatment</i> , 2022, 54, 245-252.	3.0	5
2	Utility of 3T MRI in Women with IB1 Cervical Cancer in Determining the Necessity of Less Invasive Surgery. <i>Cancers</i> , 2022, 14, 224.	3.7	3
3	Major clinical research advances in gynecologic cancer in 2021. <i>Journal of Gynecologic Oncology</i> , 2022, 33, e43.	2.2	19
4	Anxiolytic effects of chewing gum during preoperative fasting and patient-centered outcome in female patients undergoing elective gynecologic surgery: randomized controlled study. <i>Scientific Reports</i> , 2022, 12, 4165.	3.3	5
5	Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery. <i>Gynecologic Oncology</i> , 2022, , .	1.4	2
6	Safety and efficacy study of laparoscopic or robotic radical surgery using an endoscopic stapler for inhibiting tumour spillage of cervical malignant neoplasms evaluating survival (SOLUTION): a multi-centre, open-label, single-arm, phase II trial protocol. <i>BMC Cancer</i> , 2022, 22, 331.	2.6	9
7	Clinical outcome of pulmonary lymphangitic carcinomatosis in gynecologic malignancy: A single-institution experience. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2022, 61, 333-338.	1.3	3
8	Prognostic Significance of HER3 Expression in Patients with Cervical Cancer. <i>Cancers</i> , 2022, 14, 2139.	3.7	3
9	Diagnostic Accuracy of Loop-Mediated Isothermal Amplification Assay for Group B Streptococcus Detection in Recto-Vaginal Swab: Comparison with Polymerase Chain Reaction Test and Conventional Culture. <i>Diagnostics</i> , 2022, 12, 1569.	2.6	1
10	Vulvar epithelioid sarcoma: A case report with literature review. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2021, 60, 132-135.	1.3	8
11	Major clinical research advances in gynecologic cancer in 2020. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e53.	2.2	19
12	Significance of serum CA125 level in surgically resected cervical adenocarcinoma with adverse features. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e72.	2.2	3
13	The implementation of enhanced recovery after surgery protocols in ovarian malignancy surgery. <i>Gland Surgery</i> , 2021, 10, 1182-1194.	1.1	5
14	En bloc pelvic resection of ovarian cancer with rectosigmoid colectomy: a literature review. <i>Gland Surgery</i> , 2021, 10, 1195-1206.	1.1	1
15	Minimally-Invasive Versus Abdominal Hysterectomy for Endometrial Carcinoma With Glandular or Stromal Invasion of Cervix. <i>Frontiers in Oncology</i> , 2021, 11, 670214.	2.8	2
16	Single-port access (SPA) laparoscopic myomectomy with uterine artery ligation via a retroperitoneal approach is feasible in women with large uterine leiomyoma. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2021, 60, 752-757.	1.3	1
17	Early Metabolic Response Assessed Using 18F-FDG-PET/CT for Image-Guided Intracavitary Brachytherapy Can Better Predict Treatment Outcomes in Patients with Cervical Cancer. <i>Cancer Research and Treatment</i> , 2021, 53, 803-812.	3.0	2
18	Validation of Potential Protein Markers Predicting Chemoradioresistance in Early Cervical Cancer by Immunohistochemistry. <i>Frontiers in Oncology</i> , 2021, 11, 665595.	2.8	2

#	ARTICLE	IF	CITATIONS
19	Establishment and preclinical application of a patient-derived xenograft model for uterine cancer. <i>Gynecologic Oncology</i> , 2021, 162, 173-181.	1.4	6
20	Gamma Knife Radiosurgery-Based Combination Treatment Strategies Improve Survival in Patients With Central Nervous System Metastases From Epithelial Ovarian Cancer: A Retrospective Analysis of Two Academic Institutions in Korea and Taiwan. <i>Frontiers in Oncology</i> , 2021, 11, 719936.	2.8	2
21	Awareness of genetic counseling and genetic testing for hereditary gynecologic cancers among Korean healthcare providers: A survey. <i>Journal of Genetic Counseling</i> , 2021, , .	1.6	1
22	Prognostic Relevance of BRCA1 Expression in Survival of Patients With Cervical Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 770103.	2.8	2
23	Comparison of CA 125 alone and risk of ovarian malignancy algorithm (ROMA) in patients with adnexal mass: A multicenter study. <i>Current Problems in Cancer</i> , 2020, 44, 100508.	2.0	8
24	Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer. <i>Journal of Ovarian Research</i> , 2020, 13, 1.	3.0	31
25	Feasibility of Single-Port Access (SPA) Laparoscopy for Large Ovarian Tumor Suspected to Be Borderline Ovarian Tumor. <i>Frontiers in Oncology</i> , 2020, 10, 583515.	2.8	4
26	Validation of IOTA-ADNEX Model in Discriminating Characteristics of Adnexal Masses: A Comparison with Subjective Assessment. <i>Journal of Clinical Medicine</i> , 2020, 9, 2010.	2.4	20
27	Chloroquine reverses chemoresistance via upregulation of p21WAF1/CIP1 and autophagy inhibition in ovarian cancer. <i>Cell Death and Disease</i> , 2020, 11, 1034.	6.3	37
28	Prognostic Significance of Tumor Regression Rate during Concurrent Chemoradiotherapy in Locally Advanced Cervix Cancer: Analysis by Radiation Phase and Histologic Type. <i>Journal of Clinical Medicine</i> , 2020, 9, 3471.	2.4	8
29	Anti-Cancer Activity of As4O6 and its Efficacy in a Series of Patient-Derived Xenografts for Human Cervical Cancer. <i>Pharmaceutics</i> , 2020, 12, 987.	4.5	6
30	Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan. <i>Scientific Reports</i> , 2020, 10, 20012.	3.3	7
31	Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer. <i>Scientific Reports</i> , 2020, 10, 4904.	3.3	10
32	Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2020, 157, 437-443.	1.4	17
33	Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer. <i>Current Problems in Cancer</i> , 2020, 44, 100557.	2.0	5
34	Comparison of Laparoscopy and Laparotomy for Para-Aortic Lymphadenectomy in Women With Presumed Stage II High-Risk Endometrial Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 451.	2.8	4
35	Identification of Candidate Genes Associated with Susceptibility to Ovarian Clear Cell Adenocarcinoma Using cis-eQTL Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1137.	2.4	2
36	Pretreatment Lymph Node Metastasis as a Prognostic Significance in Cervical Cancer: Comparison between Disease Status. <i>Cancer Research and Treatment</i> , 2020, 52, 516-523.	3.0	9

#	ARTICLE	IF	CITATIONS
37	Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients. <i>Cancer Research and Treatment</i> , 2020, 52, 645-654.	3.0	13
38	Combination of a pulmonary recruitment maneuver and intraperitoneal bupivacaine for the reduction of postoperative shoulder pain in gynecologic laparoscopy: a randomized, controlled trial. <i>Obstetrics and Gynecology Science</i> , 2020, 63, 187-194.	1.6	6
39	Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer. <i>Scientific Reports</i> , 2019, 9, 15394.	3.3	27
40	Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. <i>Genome Biology</i> , 2019, 20, 253.	8.8	16
41	Prevalence and oncologic outcomes of <i>BRCA1/2</i> mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea. <i>Obstetrics and Gynecology Science</i> , 2019, 62, 411.	1.6	7
42	Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e60.	2.2	13
43	Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1333-1341.	2.5	7
44	Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 325-332.	2.3	11
45	Can simple trachelectomy or conization show comparable survival rate compared with radical trachelectomy in IA1 cervical cancer patients with lymphovascular space invasion who wish to save fertility? A systematic review and guideline recommendation. <i>PLoS ONE</i> , 2018, 13, e0189847.	2.5	11
46	Effective thermal destruction of residual tubal epithelium using an advanced sealing device in opportunistic salpingectomy: A randomized trial. <i>Gynecology and Minimally Invasive Therapy</i> , 2017, 6, 108-112.	0.9	0
47	The anti-cancer effects of itraconazole in epithelial ovarian cancer. <i>Scientific Reports</i> , 2017, 7, 6552.	3.3	37
48	Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e22.	2.2	38
49	Perioperative administration of propranolol to women undergoing ovarian cancer surgery: A pilot study. <i>Obstetrics and Gynecology Science</i> , 2017, 60, 170.	1.6	33
50	Laparoendoscopic single-site radical hysterectomy for early stage cervical cancer. <i>Obstetrics and Gynecology Science</i> , 2017, 60, 110.	1.6	3
51	Extrauterine epithelioid trophoblastic tumor in hysterectomized woman. <i>Obstetrics and Gynecology Science</i> , 2017, 60, 124.	1.6	18
52	Catamenial hemoptysis accompanied by subcutaneous endometriosis treated with combination therapy. <i>Obstetrics and Gynecology Science</i> , 2017, 60, 236.	1.6	2
53	Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 635-642.	3.0	10
54	Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies. <i>Cancer Research and Treatment</i> , 2017, 49, 915-926.	3.0	58

#	ARTICLE	IF	CITATIONS
55	Time-lapse imaging of sentinel lymph node using indocyanine green with near-infrared fluorescence imaging in early endometrial cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e27.	2.2	11
56	Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e46.	2.2	9
57	Retroperitoneal Approach in Single-Port Laparoscopic Hysterectomy. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2016, 20, e2016.00001.	1.1	4
58	Outcomes of laparoscopic fertility-sparing surgery in clinically early-stage epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e20.	2.2	17
59	Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e24.	2.2	6
60	Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis. <i>Gynecologic Oncology</i> , 2016, 143, 252-257.	1.4	20
61	Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2016, 56, 639-647.	1.0	14
62	Women with double primary cancers of the colorectum and endometrium: do they have Lynch syndrome?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 199, 208-212.	1.1	4
63	Clinical outcomes of primary surgical treatment for acquired vulvar lymphangioma circumscriptum. <i>Archives of Gynecology and Obstetrics</i> , 2016, 293, 157-162.	1.7	18
64	Dynamin 2 Inhibitors as Novel Therapeutic Agents Against Cervical Cancer Cells. <i>Anticancer Research</i> , 2016, 36, 6381-6388.	1.1	13
65	Prognostic model for disease-free survival, lymphatic and/or hematogenous recurrence, in patients with early stage cervical cancer treated with radical hysterectomy: A Korean Gynecologic Oncology Group Study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17000-e17000.	1.6	0
66	Robotic high para-aortic lymph node dissection with high port placement using same port for pelvic surgery in gynecologic cancer patients. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 222.	2.2	2
67	Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification. <i>Obstetrics and Gynecology Science</i> , 2015, 58, 124.	1.6	45
68	Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. <i>Oncotarget</i> , 2015, 6, 35040-35050.	1.8	48
69	Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer. <i>Oncotarget</i> , 2015, 6, 26746-26756.	1.8	55
70	The effect of coexisting squamous cell lesions on prognosis in patients with cervical adenocarcinoma in situ. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 190, 26-30.	1.1	5
71	Pancreatic adenocarcinoma up-regulated factor expression is associated with disease-specific survival in cervical cancer patients. <i>Human Pathology</i> , 2015, 46, 884-893.	2.0	17
72	Borderline ovarian tumor in women aged ≥65 years: impact on recurrence and survival. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 184, 38-42.	1.1	11

#	ARTICLE	IF	CITATIONS
73	A prospective comparative study of cosmetic satisfaction for three different surgical approaches. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 190, 48-51.	1.1	6
74	Robotic Single-port Hysterectomy, Adnexectomy, and Lymphadenectomy in Endometrial Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 322.	0.6	24
75	Is laparoendoscopic single-site surgery (LESS) retroperitoneal hysterectomy feasible?: Surgical outcomes of the initial 27 cases. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2015, 54, 150-154.	1.3	4
76	Fibromyxoid variant of endometrial stromal sarcoma with atypical bizarre nuclei. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3316-21.	0.5	9
77	Mesothelial cell inclusions in pelvic and para-aortic lymph nodes: a clinicopathologic analysis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5318-26.	0.5	3
78	Analysis of clinical outcomes of patients with adenoid cystic carcinoma of Bartholin glands. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5688-94.	0.5	10
79	Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer. <i>Obstetrics and Gynecology Science</i> , 2014, 57, 28.	1.6	27
80	Dual targeting of angiotensin receptors (AGTR1 and AGTR2) in epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2014, 135, 108-117.	1.4	29
81	Postoperative outcomes of MR-invisible stage IB1 cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 168.e1-168.e7.	1.3	16
82	Laparoendoscopic single-site (LESS) myomectomy: characteristics of the appropriate myoma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 175, 58-61.	1.1	15
83	Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2014, 53, 343-347.	1.3	19
84	Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: A multicenter review of 114 cases. <i>Gynecologic Oncology</i> , 2014, 132, 70-75.	1.4	63
85	Surgical Outcomes of a New Approach to Laparoscopic Myomectomy: Single-Port and Modified Suture Technique. <i>Journal of Minimally Invasive Gynecology</i> , 2014, 21, 580-585.	0.6	31
86	Genetic profiling to predict recurrence of early cervical cancer. <i>Gynecologic Oncology</i> , 2013, 131, 650-654.	1.4	52
87	Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis. <i>Anticancer Research</i> , 2013, 33, 4675-81.	1.1	9
88	Clinical significance of changes in peripheral lymphocyte count after surgery in early cervical cancer. <i>Gynecologic Oncology</i> , 2012, 127, 107-113.	1.4	22
89	Dynamin 2 expression as a biomarker in grading of cervical intraepithelial neoplasia. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012, 164, 180-184.	1.1	3
90	Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: Comparison with SCC-Ag level. <i>Gynecologic Oncology</i> , 2012, 124, 92-97.	1.4	81

#	ARTICLE	IF	CITATIONS
91	Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma. <i>Anticancer Research</i> , 2012, 32, 1555-61.	1.1	97
92	The effect of high-intensity focused ultrasound in combination with cisplatin using a Xenograft model of cervical cancer. <i>Anticancer Research</i> , 2012, 32, 5285-9.	1.1	3
93	A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. <i>Gynecologic Oncology</i> , 2011, 120, 439-443.	1.4	74
94	Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 2011, 122, 361-365.	1.4	73
95	Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: A meta-analysis. <i>Gynecologic Oncology</i> , 2011, 122, 541-547.	1.4	98
96	Glucose as a prognostic factor in non-diabetic women with locally advanced cervical cancer (IB-IVA). <i>Gynecologic Oncology</i> , 2010, 116, 459-463.	1.4	18
97	Sequence-dependent hematologic side effects of topotecan and cisplatin in persistent or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2010, 119, 87-91.	1.4	5
98	Low dynamin 2 expression is associated with tumor invasion and metastasis in invasive squamous cell carcinoma of cervix. <i>Cancer Biology and Therapy</i> , 2010, 10, 329-335.	3.4	16
99	The use of misoprostol before hysteroscopic surgery in non-pregnant premenopausal women: a randomized comparison of sublingual, oral and vaginal administrations. <i>Human Reproduction</i> , 2010, 25, 1942-1948.	0.9	26
100	Factors influencing the choice of laparoscopy or laparotomy in pregnant women with presumptive benign ovarian tumors. <i>International Journal of Gynecology and Obstetrics</i> , 2010, 108, 12-15.	2.3	16
101	Single port access laparoscopic adnexal surgery versus conventional laparoscopic adnexal surgery: a comparison of peri-operative outcomes. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2010, 151, 181-184.	1.1	97
102	The prognostic significance of the SUVmax (maximum standardized uptake value for F-18) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 307 Td results. <i>Gynecologic Oncology</i> , 2009, 115, 65-68.	1.4	78
103	Single-Port Access Laparoscopic-Assisted Vaginal Hysterectomy: A Novel Method with a Wound Retractor and a Glove. <i>Journal of Minimally Invasive Gynecology</i> , 2009, 16, 450-453.	0.6	126